Literature DB >> 7677469

Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. A case-control study.

A K Chan1, Q Y Duh, M H Katz, A E Siperstein, O H Clark.   

Abstract

BACKGROUND: There has been an National Institutes of Health consensus meeting concerning the management of patients with "asymptomatic" primary hyperparathyroidism, yet there is no clear definition of this condition. The authors, therefore, documented the clinical manifestations and frequencies of these manifestations in unselected patients with primary hyperparathyroidism and determined whether these clinical manifestations resolved after parathyroidectomy.
METHOD: The authors studied 152 unselected consecutive patients with primary hyperparathyroidism and 132 control patients with nontoxic thyroid disorders who were treated by parathyroidectomy or thyroidectomy, respectively, between January 1986 and June 1991. All patients received a questionnaire during their initial office visits and the same questionnaire again after their operations. Patients were also questioned about their perception of the success of the operation. Eighty percent of the parathyroid patients and 70.5% of the thyroid patients completed the questionnaires, and the mean follow-up time was 20 months.
RESULTS: Only 7 (4.6%) patients with primary hyperparathyroidism had no symptoms, and 26 (17.1%) had no associated conditions despite 74.3% of these patients having serum calcium levels less than 12 mg/dL. Symptoms including fatigue, exhaustion, weakness, polydipsia, polyuria, nocturia, joint pain, bone pain, constipation, depression, anorexia, nausea, heartburn, and associated conditions, including nephrolithiasis, and hematuria occurred more often in patients with primary hyperparathyroidism than in the thyroid control patients (p < 0.05). After parathyroidectomy, only eight (5.3%) patients failed to have any improvement in symptoms or associated conditions. Fifty-seven percent of the parathyroid patients versus 30% of the thyroid patients felt better overall after the operation, strength subjectively improved in 29% of parathyroid patients versus 13% in thyroid patients; thirty-seven percent of the parathyroid patients versus 13% of the thyroid patients claimed they were less depressed.
CONCLUSION: When examined thoroughly, few patients with primary hyperparathyroidism were asymptomatic or without associated conditions, and most patients experienced subjective improvement after successful parathyroidectomy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7677469      PMCID: PMC1234827          DOI: 10.1097/00000658-199509000-00017

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  31 in total

1.  Characterization and evaluation of asymptomatic primary hyperparathyroidism.

Authors:  J P Bilezikian; S J Silverberg; E Shane; M Parisien; D W Dempster
Journal:  J Bone Miner Res       Date:  1991-10       Impact factor: 6.741

Review 2.  Clinical Review 9: Management of asymptomatic hyperparathyroidism.

Authors:  J T Potts
Journal:  J Clin Endocrinol Metab       Date:  1990-06       Impact factor: 5.958

Review 3.  Primary hyperparathyroidism. A surgical perspective.

Authors:  O H Clark; Q Y Duh
Journal:  Endocrinol Metab Clin North Am       Date:  1989-09       Impact factor: 4.741

4.  Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay.

Authors:  R C Brown; J P Aston; I Weeks; J S Woodhead
Journal:  J Clin Endocrinol Metab       Date:  1987-09       Impact factor: 5.958

5.  Causes of death in patients previously operated on for primary hyperparathyroidism.

Authors:  H Ronni-Sivula
Journal:  Ann Chir Gynaecol       Date:  1985

6.  Studies in patients with hyperparathyroidism using a new two-site immunochemiluminometric assay for circulating intact (1-84) parathyroid hormone.

Authors:  I R Curley; M H Wheeler; J P Aston; R C Brown; I Weeks; J S Woodhead
Journal:  Surgery       Date:  1987-12       Impact factor: 3.982

Review 7.  Diagnosis and management of asymptomatic hyperparathyroidism: safety, efficacy, and deficiencies in our knowledge.

Authors:  O H Clark; W Wilkes; A E Siperstein; Q Y Duh
Journal:  J Bone Miner Res       Date:  1991-10       Impact factor: 6.741

8.  Mortality after surgery for primary hyperparathyroidism: a follow-up of 441 patients operated on from 1956 to 1979.

Authors:  M Palmér; H O Adami; R Bergström; G Akerström; S Ljunghall
Journal:  Surgery       Date:  1987-07       Impact factor: 3.982

9.  Improvement of muscle strength after treatment for hyperparathyroidism.

Authors:  I Hedman; G Grimby; L E Tisell
Journal:  Acta Chir Scand       Date:  1984

10.  Survival and renal function in untreated hypercalcaemia. Population-based cohort study with 14 years of follow-up.

Authors:  M Palmer; H O Adami; R Bergström; S Jakobsson; G Akerström; S Ljunghall
Journal:  Lancet       Date:  1987-01-10       Impact factor: 79.321

View more
  34 in total

1.  Vitamin D, parathyroid hormone, and cardiovascular events among older adults.

Authors:  Bryan Kestenbaum; Ronit Katz; Ian de Boer; Andy Hoofnagle; Mark J Sarnak; Michael G Shlipak; Nancy S Jenny; David S Siscovick
Journal:  J Am Coll Cardiol       Date:  2011-09-27       Impact factor: 24.094

2.  Elevated parathyroid hormone after parathyroidectomy delays symptom improvement.

Authors:  Priya R Pathak; Sara E Holden; Sarah C Schaefer; Glen Leverson; Herbert Chen; Rebecca S Sippel
Journal:  J Surg Res       Date:  2014-03-02       Impact factor: 2.192

3.  The outcome of cervical exploration for asymptomatic and symptomatic patients with primary hyperparathyroidism.

Authors:  Jaber S Abbas; Suzan I Hashem; Walid G Faraj; Mohammad J Khalifeh; Mukbil H Horani; Ibrahim S Salti
Journal:  World J Surg       Date:  2006-01       Impact factor: 3.352

4.  Regional cerebral blood flow abnormalities in patients with primary hyperparathyroidism.

Authors:  Tevfik Fikret Cermik; Meryem Kaya; Betül Uğur-Altun; Deniz Bedel; Sakir Berkarda; Omer N Yiğitbaşi
Journal:  Neuroradiology       Date:  2007-01-05       Impact factor: 2.804

5.  Surgical cure of primary hyperparathyroidism ameliorates gastroesophageal reflux symptoms.

Authors:  James Norman; Douglas Politz; Jose Lopez; Deva Boone; Alexander Stojadinovic
Journal:  World J Surg       Date:  2015-03       Impact factor: 3.352

6.  Normalization of 2-week postoperative parathyroid hormone values in patients with primary hyperparathyroidism: four-gland exploration compared to focused-approach surgery.

Authors:  Peter J Mazzaglia; Mira Milas; Eren Berber; Alan Siperstein; Jack M Monchik
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

Review 7.  What symptom improvement can be expected after operation for primary hyperparathyroidism?

Authors:  Nadine R Caron; Janice L Pasieka
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

8.  Timing of symptom improvement after parathyroidectomy for primary hyperparathyroidism.

Authors:  Sara E Murray; Priya R Pathak; David S Pontes; David F Schneider; Sarah C Schaefer; Herbert Chen; Rebecca S Sippel
Journal:  Surgery       Date:  2013-10-04       Impact factor: 3.982

9.  Clinical presentation and management of patients with primary hyperparathyroidism of the Swiss Primary Hyperparathyroidism Cohort: a focus on neuro-behavioral and cognitive symptoms.

Authors:  A Trombetti; E R Christ; C Henzen; G Gold; M Brändle; F R Herrmann; C Torriani; F Triponez; M Kraenzlin; R Rizzoli; C Meier
Journal:  J Endocrinol Invest       Date:  2016-01-07       Impact factor: 4.256

10.  Allosteric modulation of the calcium-sensing receptor.

Authors:  Anders A Jensen; Hans Bräuner-Osborne
Journal:  Curr Neuropharmacol       Date:  2007-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.